Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility

• Initial drawdown of A$17M completed under A$34M non-dilutive funding facility
• Funds to support ACTION3 Phase 3 trial and DMX-652 development
• Remaining A$17M available for future draw-down until March 2027

Dimerix Limited, a clinical-stage biopharmaceutical company focused on kidney disease treatments, has drawn down A$17 million from a previously announced A$34 million non-dilutive funding facility. This drawdown represents 50% of the committed amount and is intended to support the company's planned activities, including the ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis (FSGS) and the Phase 2 trial of DMX-652 for Acute Kidney Injury (AKI). The funding significantly strengthens Dimerix's balance sheet and provides financial flexibility as the company progresses its clinical and commercial milestones. The remaining A$17 million can be drawn down at Dimerix's discretion until March 2027, subject to facility terms.